A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -1.48% this year. Over the last six months, there has been a weaker performance of 29.93%. The price of SGMT fallen by 71.15% during the last 30 days period. For the last 5-days stocks have slided -5.49%.
Sagimet Biosciences Inc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $20.71 on 01/22/24, while the lowest value for the same period was recorded at $2.13 on 11/13/23.
52-week price history of SGMT Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Sagimet Biosciences Inc’s current trading price is -74.22% away from its 52-week high, while its distance from the 52-week low is 150.70%. The stock’s price range during this period has varied between$2.13 and $20.71. The Sagimet Biosciences Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.72 million for the day, a figure considerably lower than their average daily volume of 1.33 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Sagimet Biosciences Inc (SGMT) has experienced a quarterly rise of 53.45% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 163.80M and boasts a workforce of 10 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.65, with a change in price of +0.64. Similarly, Sagimet Biosciences Inc recorded 1,056,839 in trading volume during the last 100 days, posting a change of +13.62%.
SGMT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SGMT stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
SGMT Stock Stochastic Average
As of today, Sagimet Biosciences Inc’s raw stochastic average for the last 50 days stands at 74.41%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 67.34%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 82.75% and 86.51%, respectively.
